AnaptysBio Inc reports results for the quarter ended June 30 - Earnings Summary

• AnaptysBio Inc ANAB.OQ reported a quarterly adjusted loss of $1.34​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.71. The mean expectation of eleven analysts for the quarter was for a loss of $1.54 per share. Wall Street expected results to range from $-1.85 to -89 cents per share.

• Revenue rose 102.9% to $22.26 million from a year ago; analysts expected $11.55 million.

• AnaptysBio Inc's reported EPS for the quarter was a loss of $1.34​.

• AnaptysBio Inc shares had risen by 6.7% this quarter and gained 78.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 2.7% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for AnaptysBio Inc is $45.50, about 47.9% above its last closing price of $23.69

This summary was machine generated from LSEG data August 6 at 09:04 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)